marketing@medicilon.com

ABOUT

Company Profile

Corporate Culture

Management Team

Company History

Message from the CEO

Honors and Awards

SERVICES

01 Drug Discovery

Chemistry Research Biology Research Early Pharmacokinetics

02 Pharmaceutical Research

Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center

03 Preclinical Research

Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings

PLATFORM

01 One-stop Integrated Services

Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D

02 Innovative Drug R&D Services

Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC

03 Key Technical Services for Drug R&D

Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration

04 Drug Efficacy Evaluation for Common Diseases

Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model

05 High-end Preparations Technology Platform

Skin Topical Preparation Ophthalmic drug Inhalation drug

06 Targeted Drugs R&D Services

STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service

07 Safety Assessment Lab of Process Chemistry

08 Public Services

CAREERS

Talent Development

Campus Recruitment

Recruitment

NEWS

Medicilon Events

Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use

2022-08-29

Page View：

On August 8, 2022, Cullgen Inc announced the approval of the IND application for a TRK degrader (CG001419) for the treatment of advanced solid tumors. CG001419 is the world's first in class TRK (neurotrophic factor receptor tyrosine kinase) protein degrader.

Shanghai Medicilon Inc., as the collaborative CRO of Cullgen, relies on the PROTAC technology platform to provide comprehensive preclinical research services that comply with both China and US GLP standards for the R&D of CG001419 (including pharmacokinetic research and safety evaluation) and helped CG001419 to successfully get approved.

new-drug-TRK-degrader-CG001419